Pharmacy and medical group Green Cross Health has reported its strongest annual profit in years, lifting net earnings 28 percent even as it lines up the sale of the doctor network that did much of the heavy lifting.
The company, which owns the Unichem and Life Pharmacy brands and The Doctors network of medical centres, told the New Zealand stock exchange that net profit after tax climbed to 20.4 million dollars for the year to 31 March 2026, up from a much thinner result the year before. Operating revenue rose 4 percent to 546 million dollars and operating profit, the figure most analysts watch, jumped 17 percent to 45.3 million dollars. You can read the full numbers in the company’s market announcement.
It is a notable turnaround for a business that has spent the past two years absorbing rising costs, soft consumer spending and a health system under strain. Chair Kim Ellis struck a measured tone, saying the company remained cautious about consumer sentiment and the pace of economic recovery, while group chief executive Rachael Newfield pointed to digital investment across both arms of the business as a key driver of the result.
The headline number hides a more interesting story underneath. Green Cross runs two main divisions, and they pulled in different directions. The pharmacy arm, by far the larger of the two by store count, delivered steady rather than spectacular growth. Pharmacy revenue rose just 2 percent to 380.2 million dollars and operating profit edged up 4 percent to 22.2 million dollars. The network dispensed more than 38 million prescription items over the year and administered over 330,000 vaccinations, with same store prescription volumes broadly flat. In a year when household budgets were squeezed and many shoppers traded down, holding the line counts as a decent result.
The real momentum came from the medical division. Revenue there grew 8 percent to 165.8 million dollars and operating profit surged 33 percent to 26 million dollars, meaning the medical arm now out-earns the much larger pharmacy business on an operating basis. The Doctors network spans 65 medical centres with roughly 413,000 enrolled patients, making it one of the biggest primary care operators in the country. Demand for general practice has not gone anywhere, and Green Cross has been able to grow both the top and bottom line as patients keep coming through the door.
Which is what makes the company’s next move so striking. The same medical division that just powered this result is the one Green Cross has agreed to sell. In a separate deal announced last week, primary care group Tend Health agreed to buy The Doctors network for 270 million dollars in a transaction backed by iwi investors. Green Cross has confirmed it is in discussions over the sale of its medical business, and the strong FY26 medical result effectively sets the table for that deal by showing buyers exactly what they are paying for.
It is a logical piece of corporate strategy even if the timing looks counterintuitive. Selling a division at the top of its earnings cycle tends to fetch a better price than selling one that is struggling. For Green Cross, the sale would leave it as a more focused pharmacy and community health business, with cash to pay down debt, return to shareholders or reinvest in its retail network. For Tend, a fast growing digital first primary care provider, buying an established bricks and mortar network of 65 clinics and more than 400,000 patients is a fast way to scale up. The country’s general practice sector has been consolidating for years as smaller practices struggle with workforce shortages and thin margins, and this deal continues that trend.
Green Cross also flagged that it is on track to start operating a new Primary Health Organisation from 1 July 2026. Primary Health Organisations are the bodies that channel government funding to general practices and coordinate care for enrolled populations, and running its own gives the company more control over how that money flows. How the planned medical sale interacts with that new organisation will be one of the more technical questions for investors and patients to watch in the coming months.
For the roughly 416,000 New Zealanders enrolled at a The Doctors clinic, the immediate message is that nothing changes at the front desk. Ownership deals at this level rarely alter the day to day experience of seeing a nurse or booking a repeat prescription, at least in the short term. The bigger questions are about what the combined Tend and The Doctors operation looks like over time, how aggressively it pushes digital consultations and after hours care, and whether consolidation eventually shows up in fees or wait times.
Shareholders, meanwhile, got a tangible reward. The board declared a final dividend of 5.50 cents per share, payable on 22 June 2026, a sign of confidence that the underlying business can keep generating cash even as its shape changes. RNZ and other outlets noted that the result landed in a tough retail and health market, which makes the profit lift more impressive rather than less.
The wider picture is of a New Zealand health sector that remains stretched but commercially active. Demand for both medicines and doctors is structurally strong as the population ages, and that demand is steady income for the companies that can manage costs and staffing. Green Cross has shown it can grow earnings in a hard year. The interesting test now is whether a slimmed down, pharmacy focused Green Cross can keep doing it once its fastest growing division has a new owner.
What do you make of Green Cross selling the medical arm that just delivered its best growth? Have your say in the comments below.
This article was written by AI, briefed to report the facts, hopefully without some of the bias people bring to the job π
Leave a Reply